Clinical Characteristics and Outcomes in a Population With Disseminated Herpes Zoster: A Retrospective Cohort Study

Bollea-Garlatti, M.L.; Bollea-Garlatti, L.A.; Vacas, Aldana Soledad; Torre, Ana Clara; Kowalczuk, Alicia; Galimberti, Ricardo; Ferreyro, Bruno L.

doi:10.1016/j.adengl.2016.12.019

Cited by 22 publications

(30 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study from the United States showed an increased number of hospital admissions, complications, cost burden, and prescriptions amongst older individuals secondary to VZVI. 30 The higher burden of disease in the elderly has been confirmed by other studies, 31 in which they found that the elderly, even immunocompetent without any detectable triggers were at increased risk of developing VZVI. Further analysis into the cause of this observation leads to the conclusion that immune-senescence might play an important role in the onset of VZVI in older immunocompetent patients.…”

Section: Discussionmentioning

confidence: 70%

“…Further analysis into the cause of this observation leads to the conclusion that immune-senescence might play an important role in the onset of VZVI in older immunocompetent patients. 31 Therefore, vaccination and immunoglobulins are important aspects for the prevention of VZVI in the elderly and pediatric population. [32][33][34] Our study also showed a slightly higher incidence rate of VZVI in females, which was consistent with previous research, 35 but the reason was still unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The global disease burden of varicella‐zoster virus infection from 1990 to 2019

Huang

Wang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Data on the global epidemiology of varicella-zoster virus infection (VZVI) is limited.This study aimed to investigate the burden of VZVI based on the global burden of disease study 2019 data. The age-standardized rates, including the incidence, death, disability-adjusted life years (DALYs), and the estimated annual percentage changes (EAPC) of VZVI were calculated to evaluate the disease burden of VZVI. The global numbers of incident and death cases due to VZVI were 83 963 744 and 14 553, respectively. The age-standardized incidence rate of VZVI increased slightly all over the world, while the age-standardized death and DALYs rate decreased from 1990 to 2019 (EAPC = −2.31 and −1.61, respectively). The younger age (<5 years old) and older groups had the highest VZVI burden. The high sociodemographic index (SDI) region had the highest age-standardized incidence rates in 2019 (1236.28/100 000, 95% uncertainty interval [UI]: 1156.66-1335.50) and the low SDI region had the lowest incidence (1111.24/100 000, 95% UI: 1040.46-1209.55). The agestandardized death and DALYs rate of VZVI decreased with the increase of SDI.Amongst the 21 geographical regions, the high-income Asia-Pacific (1269.08/ 100 000) region had the highest age-standardized incidence rate in 2019, while Sub-Saharan Africa had the highest age-standardized death and DALYs rate. The global incidence of VZVI has continued to increase in the past 3 decades, while the agestandardized death and DALYs rates have decreased. More attention should be paid to the younger and older population, as well as low SDI regions.disability-adjusted life years, epidemiology, global burden of disease study, incidence, varicella-zoster virus infection | INTRODUCTIONVaricella zoster virus (VZV), also known as human herpesvirus 3, is a double-stranded DNA human alphaherpesvirus. 1 Varicella-zoster virus infection (VZVI) usually leads to varicella (chickenpox) during childhood and causes herpes zoster (shingles) in the elderly. 2 The manifestation of the VZVI is vesicular pruritic rashes that appear mainly on the head, face, and trunk and may accompany a variety of complications including bacterial superinfection of the skin, pneumonia, and encephalitis. 2,3 Primary VZVI usually causes latent

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

The global disease burden of varicella‐zoster virus infection from 1990 to 2019

Huang

Wang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…VZV presents with two clinically distinct forms of disease: primary vesicular lesions (chickenpox) and secondary reactivation of HZ, in a restricted dermatomal vesicular patches or plaques (shingles) 2. It is thought that all HZ is associated with viraemia, which immunocompromised patients cannot control 3…”

Section: Descriptionmentioning

confidence: 99%

Two types of varicella zoster in one patient

Mounsey

2017

BMJ Case Reports

View full text Add to dashboard Cite

“…PHN is a chronic and persistent pain. As a typical form of neuropathic pain, patients with PHN often have hyperalgesia, spontaneous pain, sensory loss, abnormal mechanical pain, and other clinical symptoms; collectively, these symptoms can have a severe effect on the physical and mental health of patients as they are often unable to dress and walk (10,11). Clinical manifestations include persistent burning pain, shooting, stabbing, and electric shock tactile pain.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Moxibustion for Postherpetic Neuralgia: A Systematic Review and Meta-Analysis

Han

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Background: Postherpetic neuralgia (PHN) is one of the most common complications of herpes zoster (HZ), and there is still a lack of effective therapies. An increasing number of studies have found that compared to traditional therapy, moxibustion treatment is beneficial for the treatment of PHN, although current evidence remains inconclusive. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of moxibustion for PHN.Methods: We conducted a broad literature review of a range of databases from inception to December 2020, including the Cochrane Library, PubMed, EMBASE, Web of Science, Clinical Trails, China National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals (VIP), China Biomedical Network Information, and Wanfang databases. We included RCTs that compared moxibustion to pharmacological therapies, herbal medicine, or no treatment for treating PHN. The main outcome measure was efficacy rate and Visual Analog Scale (VAS); the secondary outcome measure was adverse events. Data accumulation and synthesis included meta-analysis, publication bias, sensitivity analysis, risk-of-bias assessment, and adverse events.Results: We included 13 RCTs involving 798 patients. Compared with the controls (pharmacological therapies, herbal medicine, or no treatment), moxibustion achieved a significantly higher efficacy rate (odds ratio [OR]: 3.65; 95% [confidence interval]: [2.32, 5.72]; P < 0.00001). Subgroup analysis of the distinct moxibustion modalities showed that both Zhuang medicine medicated thread and thunder-fire moxibustions obtained higher clinical efficacy than the control group. Compared with the controls, moxibustion resulted in significantly lower scores on the VAS (Weighted Mean Difference (MD) = −1.79; 95% CI: [−2.26, −1.33]; P < 0.00001). However, there was no significant difference in terms of safety between moxibustion and the controls (OR = 0.33; 95% CI [0.06, 1.77]; P = 0.19).Conclusion: Due to the lack of methodological quality as well as the significant heterogeneity of the included studies, it remains difficult to draw a firm conclusion on the efficacy and safety of moxibustion for the treatment of PHN. Future high-quality studies are urgently needed.

show abstract

Clinical Characteristics and Outcomes in a Population With Disseminated Herpes Zoster: A Retrospective Cohort Study

Abstract: This study provides evidence on the relationship between DHZ, the presence of underlying immunodepression, and complications. Immunosenescence may play an important role in the onset of this disease in older immunocompetent patients.

Cited by 22 publications

References 25 publications

The global disease burden of varicella‐zoster virus infection from 1990 to 2019

The global disease burden of varicella‐zoster virus infection from 1990 to 2019

Two types of varicella zoster in one patient

Efficacy and Safety of Moxibustion for Postherpetic Neuralgia: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About